levodopa has been researched along with Innate Inflammatory Response in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (18.18) | 29.6817 |
| 2010's | 13 (59.09) | 24.3611 |
| 2020's | 5 (22.73) | 2.80 |
| Authors | Studies |
|---|---|
| Edwards, BS; Graves, SW; Saunders, MJ; Sklar, LA; Zhu, J | 1 |
| Bourque, M; Di Paolo, T; Morissette, M; Tremblay, MÈ | 1 |
| Bekhbat, M; Felger, JC; Haroon, E; Li, Z; Lucido, MJ; Mehta, ND; Miller, AH; Treadway, MT; Woolwine, BJ | 1 |
| Egan, T; Kuriakose, A; Rentsch, P; Stayte, S; Vissel, B | 1 |
| Che, Y; Feng, X; Liu, Q; Tang, X; Zhang, S; Zhu, D | 1 |
| Bishop, C | 1 |
| Chen, J; Li, Z; Shi, J; Song, J; Su, L; Wang, J; Yang, H; Ye, J; Zhang, Y; Zhao, C | 1 |
| Antonioli, L; Ballabeni, V; Barocelli, E; Bernardini, N; Blandini, F; Blandizzi, C; Cerri, S; Colucci, R; Fornai, M; Gentile, D; Ippolito, C; Levandis, G; Pellegrini, C; Segnani, C; Tirotta, E | 1 |
| Boi, L; Carta, AR; Fenu, S; Mulas, G; Pisanu, A; Spiga, S | 1 |
| Bariotto-Dos-Santos, K; Bortolanza, M; Del-Bel, EA; Leite-Panissi, CRA; Nascimento, GC | 1 |
| Bhattacharya, P; Borah, A; Chakrabarty, J; Dutta, A; Mazumder, MK; Paul, R; Phukan, BC | 1 |
| Cova, I; Priori, A | 1 |
| Dolžan, V; Flisar, D; Georgiev, D; Kojović, M; Kramberger, MG; Pirtošek, Z; Redenšek, S; Trošt, M | 1 |
| Bishop, C; Deak, T; Lanza, K; Perkins, AE | 1 |
| Bortolanza, M; Cavalcanti-Kiwiatkoski, R; da-Silva, CA; Del-Bel, E; Mitkovski, M; Padovan-Neto, FE; Raisman-Vozari, R | 1 |
| Bhasin, MK; Blake, P; Buettner, C; Burstein, R; Papavassiliou, E; Perry, CJ; Schain, AJ | 1 |
| Bariotto, K; Bortolanza, M; Del-Bel, E; Dos-Santos-Pereira, M; Raisman-Vozari, R | 1 |
| Del Soldato, P; Giustarini, D; Rossi, R; Santus, G; Sparatore, A | 1 |
| Czub, M; Czub, S; Gosztonyi, G; Koutsilieri, E; Müller, JG; Riederer, P; Sopper, S; Stahl-Hennig, C; Ter Meulen, V; Villinger, F | 1 |
| Lang, AE; Postuma, RB | 1 |
| Hirschelmann, R; Thong, NT | 1 |
| Franceschi, C; Galeazzi, L; Giunta, S; Ronchi, P; Valli, B | 1 |
5 review(s) available for levodopa and Innate Inflammatory Response
| Article | Year |
|---|---|
Neuroinflammation in L-DOPA-induced dyskinesia: beyond the immune function.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Inflammation; Levodopa; Tumor Necrosis Factor-alpha | 2018 |
Diagnostic biomarkers for Parkinson's disease at a glance: where are we?
Topics: alpha-Synuclein; Biomarkers; Brain; Cognition Disorders; Constipation; Depression; Early Diagnosis; Genetic Predisposition to Disease; Humans; Inflammation; Levodopa; Metabolomics; Microbiota; Movement Disorders; Neuroimaging; Olfaction Disorders; Parkinson Disease; REM Sleep Behavior Disorder; Symptom Assessment; Vision Disorders | 2018 |
l-DOPA-induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?
Topics: Animals; Antiparkinson Agents; Astrocytes; Dyskinesia, Drug-Induced; Humans; Inflammation; Levodopa; Neurons; Parkinson Disease | 2016 |
Therapeutic potential of new hydrogen sulfide-releasing hybrids.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diclofenac; Humans; Hydrogen Sulfide; Inflammation; Latanoprost; Levodopa; Prodrugs; Prostaglandins F, Synthetic | 2011 |
Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy?
Topics: Antiparkinson Agents; Arteriosclerosis; Catechol O-Methyltransferase; Dementia; Disease Progression; Disease Susceptibility; Homocysteine; Humans; Hyperhomocysteinemia; Inflammation; Levodopa; Models, Biological; Multicenter Studies as Topic; Oxidative Stress; Parkinson Disease; Randomized Controlled Trials as Topic; Substantia Nigra | 2004 |
1 trial(s) available for levodopa and Innate Inflammatory Response
| Article | Year |
|---|---|
Functional connectivity in reward circuitry and symptoms of anhedonia as therapeutic targets in depression with high inflammation: evidence from a dopamine challenge study.
Topics: Adult; Anhedonia; Depression; Depressive Disorder, Major; Dopamine; Humans; Inflammation; Levodopa; Magnetic Resonance Imaging; Neural Pathways; Reward | 2022 |
16 other study(ies) available for levodopa and Innate Inflammatory Response
| Article | Year |
|---|---|
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Proteins; High-Throughput Screening Assays; Humans; Inflammation; Kinetics; Microspheres; Peptide Hydrolases; Peptides; Reproducibility of Results; Temperature | 2010 |
Prevention of L-Dopa-Induced Dyskinesias by MPEP Blockade of Metabotropic Glutamate Receptor 5 Is Associated with Reduced Inflammation in the Brain of Parkinsonian Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Dyskinesia, Drug-Induced; Humans; Inflammation; Levodopa; Macaca fascicularis; Parkinson Disease; Pyridines; Receptor, Metabotropic Glutamate 5 | 2022 |
The ratio of M1 to M2 microglia in the striatum determines the severity of L-Dopa-induced dyskinesias.
Topics: Animals; Anti-Inflammatory Agents; Antiparkinson Agents; Corpus Striatum; Dyskinesias; Indomethacin; Inflammation; Levodopa; Mice; Microglia; Minocycline; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2023 |
The parthenolide derivative ACT001 synergizes with low doses of L-DOPA to improve MPTP-induced Parkinson's disease in mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antiparkinson Agents; Apoptosis; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Inflammation; Levodopa; Male; Mice; Mice, Inbred BALB C; Nerve Degeneration; Parkinson Disease; Parkinsonian Disorders; Sesquiterpenes | 2020 |
Neuroinflammation: Fanning the fire of l-dopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Cytokines; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Inflammation; Levodopa; Nervous System Diseases; Tumor Necrosis Factor-alpha | 2019 |
Structural Transformative Antioxidants for Dual-Responsive Anti-Inflammatory Delivery and Photoacoustic Inflammation Imaging.
Topics: Anti-Inflammatory Agents; Antioxidants; Boronic Acids; Contrast Media; Humans; Hydrophobic and Hydrophilic Interactions; Inflammation; Levodopa; Nanoparticles; Photoacoustic Techniques; Reactive Oxygen Species | 2021 |
Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration.
Topics: Acetylcholine; Administration, Oral; Animals; Antiparkinson Agents; Benserazide; Choline O-Acetyltransferase; Colon; Gastrointestinal Transit; Inflammation; Interleukin-1beta; Levodopa; Male; Muscle, Smooth; Oxidopamine; Parkinsonian Disorders; Rats, Sprague-Dawley; Synaptic Transmission; Tissue Culture Techniques; Tumor Necrosis Factor-alpha | 2017 |
Nociceptive Response to L-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Inflammation; Levodopa; Male; Nociceptive Pain; Oxidopamine; Parkinsonian Disorders; Pars Compacta; Rats, Wistar | 2018 |
Garcinol, an effective monoamine oxidase-B inhibitor for the treatment of Parkinson's disease.
Topics: Humans; Inflammation; Isoxazoles; Levodopa; Ligands; Molecular Conformation; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Oxidative Stress; Parkinson Disease; Phytochemicals; Phytotherapy; Reactive Oxygen Species; Terpenes; Zonisamide | 2018 |
Genetic variability of inflammation and oxidative stress genes does not play a major role in the occurrence of adverse events of dopaminergic treatment in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Female; Genetic Predisposition to Disease; Genotype; Humans; Inflammation; Levodopa; Male; Oxidative Stress; Parkinson Disease; Polymorphism, Single Nucleotide | 2019 |
Late aging-associated increases in L-DOPA-induced dyskinesia are accompanied by heightened neuroinflammation in the hemi-parkinsonian rat.
Topics: Aging; Animals; Dyskinesia, Drug-Induced; Gene Expression; Inflammation; Interleukin-1beta; Interleukin-6; Levodopa; Male; Parkinson Disease; Rats; Rats, Inbred F344; Risk Factors | 2019 |
Glial activation is associated with l-DOPA induced dyskinesia and blocked by a nitric oxide synthase inhibitor in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Indazoles; Inflammation; Levodopa; Male; Neuroglia; Neuroprotective Agents; Nitric Oxide; Nitric Oxide Synthase; Parkinson Disease; Rats; Rats, Wistar; Up-Regulation | 2015 |
Upregulation of inflammatory gene transcripts in periosteum of chronic migraineurs: Implications for extracranial origin of headache.
Topics: Adolescent; Adult; Aged; Biomarkers; Case-Control Studies; Cephaloridine; Chronic Disease; Fasting; Female; Gene Expression; Gene Expression Profiling; Humans; Inflammation; Isoflurane; Lectins, C-Type; Levodopa; Male; Middle Aged; Migraine Disorders; NF-KappaB Inhibitor alpha; Periosteum; Receptors, Immunologic; Receptors, Interleukin-1 Type II; Tumor Necrosis Factor alpha-Induced Protein 3; Young Adult | 2016 |
Modulation of simian immunodeficiency virus neuropathology by dopaminergic drugs.
Topics: Animals; Cell Count; Central Nervous System Viral Diseases; Dopamine Agents; Dose-Response Relationship, Drug; Gene Expression; Immunohistochemistry; In Situ Hybridization; Inflammation; Interleukin-1; Interleukin-6; Levodopa; Macaca mulatta; Monoamine Oxidase; Selegiline; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Staining and Labeling; Statistics, Nonparametric; Time Factors; Tumor Necrosis Factor-alpha; Virus Replication | 2004 |
Influence of dopaminergic anti-Parkinsonian agents on inflammatory reactions in rats.
Topics: Animals; Antiparkinson Agents; Arthritis, Experimental; Benserazide; Bromocriptine; Carrageenan; Dopamine Agents; Edema; Evans Blue; Female; Inflammation; Levodopa; Rats; Rats, Wistar | 2000 |
Transformation of beta-amyloid (A beta) (1-42) tyrosine to L-dopa as the result of in vitro hydroxyl radical attack.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Chromatography, High Pressure Liquid; Humans; Hydroxyl Radical; Hydroxylation; Inflammation; Levodopa; Oxidation-Reduction; Oxidative Stress; Peptide Fragments; Tyrosine | 2000 |